 |
Jounce Therapeutics
Last updated: April 19, 2024
Richard Murray, CEO
Country: USA | Funding: $194.2M (+)
Website: http://jouncetx.com/
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
Website: http://jouncetx.com/
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
